SIL KASALLIGINING MIKROBIOLOGIK VA EPEDIMIOLOGIK XUSUSIYATLARI
;
tuberkulyoz, sil kasalligi, Mycobacterium tuberculosis, diagnostika, davolash, BCG vaksina, epidemiologiya, profilaktikaAbstrak
Ushbu adabiyotlar tahlilida sil (tuberkulyoz) kasalligining zamonaviy epidemiologiyasi, etiologiyasi, diagnostikasi, davolash va profilaktika usullari so‘nggi yillardagi ilmiy manbalar asosida o‘rganildi. Tuberkulyoz dunyo bo‘yicha eng muhim yuqumli kasalliklardan biri bo‘lib, asosan Mycobacterium tuberculosis bakteriyasi tomonidan chaqiriladi. Kasallik nafas yo‘llari orqali yuqib, o‘pka hamda boshqa organlarni zararlashi mumkin. Hozirgi kunda sil kasalligini aniqlashda molekulyar testlar, rentgenologik tekshiruvlar va bakteriologik usullar keng qo‘llanilmoqda. Davolash jarayonida esa uzoq muddatli kombinatsiyalangan antituberkulyoz preparatlar qo‘llaniladi. Shuningdek, BCG vaksinasi kasallikning og‘ir shakllarini oldini olishda muhim ahamiyatga ega.
Iqtiboslar
World Health Organization. Global Tuberculosis Report 2024. Geneva: WHO; 2024.
World Health Organization. Global Tuberculosis Report 2025. Geneva: WHO; 2025.
Dheda K, Gumbo T, Maartens G, et al. The epidemiology and management of drug-resistant tuberculosis. Lancet Respir Med. 2024;12(2):e20–e35. doi:10.1016/S2213-2600(23)00412-5.
Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2023;9:25. doi:10.1038/s41572-023-00394-1.
Tiberi S, Vjecha MJ, Zumla A, et al. Advances in tuberculosis diagnostics and treatment. Lancet Respir Med. 2024;12(1):45–60.
Nahid P, Dorman SE, Alipanah N, et al. Treatment of drug-susceptible tuberculosis: updated guidelines. Clin Infect Dis. 2023;76(5):e1120–e1130.
Migliori GB, Thong PM, Akkerman OW, et al. Multidrug-resistant tuberculosis management. Eur Respir J. 2024;63(1):2300456.
Lawn SD, Zumla AI. Tuberculosis. Lancet. 2023;401(10379):123–136.
Steingart KR, Sohn H, Schiller I, et al. Xpert MTB/RIF assay for pulmonary tuberculosis. Cochrane Database Syst Rev. 2023; (issue): CD009593.
Getahun H, Matteelli A, Chaisson RE, et al. Latent tuberculosis infection: updated perspectives. Eur Respir J. 2024;63(2):2202125.
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3 – Diagnosis. Geneva: WHO; 2023.
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4 – Treatment. Geneva: WHO; 2024.
Zumla A, Chakaya J, Hoelscher M, et al. Tuberculosis: a global health challenge. N Engl J Med. 2023;389:123–134.
Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays in TB diagnosis. Lancet Infect Dis. 2023;23(4):e112–e120.
Orenstein EW, Basu S, Shah NS, et al. Tuberculosis screening strategies. Clin Chest Med. 2024;45(2):245–260.
Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis epidemiology and control strategies. Lancet. 2023;402:210–220.
Centers for Disease Control and Prevention (CDC). Tuberculosis (TB): Data and Statistics. 2024.
Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Disease Control Priorities. 3rd ed. World Bank; 2023.
Horsburgh CR Jr, Barry CE, Lange C. Treatment of tuberculosis. N Engl J Med. 2023;389:234–245.
Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination. Eur Respir J. 2024;63:2301580.
MacNeil A, Glaziou P, Sismanidis C, et al. Global epidemiology of tuberculosis. Int J Infect Dis. 2023;130:45–52.
Chakaya J, Khan M, Ntoumi F, et al. Global tuberculosis control and elimination. Lancet. 2024;403:987–1002.
Fox GJ, Schaaf HS, Mandalakas AM, et al. Prevention of tuberculosis in high-risk groups. Clin Infect Dis. 2023;77(6):1012–1020.
,Zumla A, George A, Sharma V, et al. Host-directed therapies for tuberculosis. Lancet Infect Dis. 2024;24(1):e10–e22.
World Health Organization. BCG vaccine position paper. Wkly Epidemiol Rec. 2023;98(4):41–60.
##submission.downloads##
Nashr qilingan
Nashr
Bo'lim
Iqtibos keltirish tartibi
